Home » Stocks » TPST

Tempest Therapeutics, Inc. (TPST)

Stock Price: $15.81 USD 0.03 (0.19%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Market Cap 104.93M
Revenue (ttm) n/a
Net Income (ttm) -32.80M
Shares Out 1.27M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $15.81
Previous Close $15.78
Change ($) 0.03
Change (%) 0.19%
Day's Open 15.15
Day's Range 15.00 - 16.37
Day's Volume 597,943
52-Week Range 10.39 - 41.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%.  A strategic portfolio of targeted ther...

2 weeks ago - Benzinga

Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild ...

2 weeks ago - Benzinga

Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as S...

2 weeks ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...

2 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that co...

3 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics...

4 weeks ago - GlobeNewsWire

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

Other stocks mentioned: MLND
1 month ago - GlobeNewsWire

NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...

Other stocks mentioned: MLND
3 months ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...

Other stocks mentioned: MLND
3 months ago - Business Wire

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

Other stocks mentioned: MLND
3 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair t...

Other stocks mentioned: MLND
3 months ago - Business Wire

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics mo...

Other stocks mentioned: MLND
3 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.

Other stocks mentioned: MLND
3 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.

Other stocks mentioned: MLND
6 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.

Other stocks mentioned: MLND
8 months ago - Business Wire

There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the s...

Other stocks mentioned: CGA, MLND, UTSI
9 months ago - GuruFocus

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with sig...

Other stocks mentioned: MLND
10 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences

Other stocks mentioned: MLND
10 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Other stocks mentioned: MLND
11 months ago - Business Wire

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Other stocks mentioned: MLND
11 months ago - Business Wire

Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.

Other stocks mentioned: MLND
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.

Other stocks mentioned: MLND
1 year ago - Zacks Investment Research

Millendo Therapeutics: A Forgotten Biotech With Strong Potential

Other stocks mentioned: MLND
1 year ago - Seeking Alpha

Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wedbush.

Other stocks mentioned: MLND
2 years ago - Benzinga

It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.

Other stocks mentioned: MLND
2 years ago - 24/7 Wall Street

About TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate s... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Julia Owens
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
TPST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for TPST is 23.00, which is an increase of 45.48% from the latest price.

Price Target
$23.00
(45.48% upside)